Markets

Amedisys: Balanced Growth on Strategic Buyouts, Demography

A generic image of a stock chart
Credit: Shutterstock photo

On Dec 14, 2015, we issued an updated research report on Amedisys Inc.AMED , a provider of home health and hospice services across the U.S.

In third-quarter 2015, Amedisys reported solid top and bottom-line beats over the Zacks Consensus Estimate. The company witnessed balanced revenue growth in both its Home Health and Hospice divisions.

In Home Health, the company continued to generate strong organic growth in Medicare and non-Medicare revenues. In Hospice, Amedisys successfully posted strong quarterly same-store revenue growth. Going ahead, Hospice growth prospects remain strong as the Centers for Medicare & Medicaid Services' (CMS) programs will help drive increased adoption of hospice benefit.

The home health industry is poised for tremendous growth in the long term, driven by an aging U.S. population, patients' desire for greater independence, and home health as a cheaper care modality. Amedisys is expected to consistently benefit from the aging demographics of the U.S. population and the need for higher acuity patients to be taken care of in a home nursing environment.

We are also upbeat about the company's initiative to drive organic growth as well as its search for strategically fit merger and acquisition activities. Notably, the company is developing and acquiring new business lines that will complement its existing home care and hospice business and help seniors manage their health more effectively while staying in their homes longer. It is also working to develop or acquire new business lines that are focused on managing patients' age-related diseases from their onset till the end of life.

On the flip side, the market for home health and hospice is essentially fragmented with a number of small local providers and few barriers to entry. On this account, Amedisys faces tough competition primarily from local private, public and hospital-owned health care providers. Also, reimbursement rate cuts arising out of Medicare reforms pose challenges to the stock.

Currently, Amedisys carries a Zacks Rank #2 (Buy).

Key Picks in the Sector

Some other top-ranked med-outpatient/home care stocks are AmSurg Corp. AMSG , Chemed Corp. CHE and PharMerica Corporation PMC . All the three stocks carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AMEDISYS INC (AMED): Free Stock Analysis Report

AMSURG CORP (AMSG): Free Stock Analysis Report

PHARMERICA CORP (PMC): Free Stock Analysis Report

CHEMED CORP (CHE): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AMED CHE

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More